U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123129) titled 'A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors' on Aug. 07.
Brief Summary: The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Malignancy
Intervention:
DRUG: SHR-7782 Injection
SHR-7782 injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....